An alternative method of targeted delivery of a PD-1-blocking scFv by CAR-T cells not only enhanced the anti-tumor efficacy of CAR-T but also improved bystander tumor-specific T cells in xenogeneic mouse models of PD-L1+ hematologic and solid tumors (92). Here, CD274 is linked to neoplasm.